BTIG analyst Dane Leone reiterated a Buy rating on Galapagos NV (NASDAQ: GLPG) on June 13 and set a price target of $118. The company’s shares opened today at $97.62.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 20.8% and a 71.8% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Vertex Pharmaceuticals, and Blueprint Medicines.
Currently, the analyst consensus on Galapagos NV is Moderate Buy and the average price target is $118, representing a 20.9% upside.
In a report issued on May 30, Cowen & Co. also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $121.09 and a one-year low of $72.90. Currently, Galapagos NV has an average volume of 108.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
